Chronische Nierschade - Kwaliteitskoepel

kwaliteitskoepel.nl
  • No tags were found...

Chronische Nierschade - Kwaliteitskoepel

Richtlijn Chronische Nierschade, 2009REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).Ramipril Efficacy in Nephropathy. Lancet 1998; 352: 1252-125683. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on theprogression of nondiabetic renal disease: a meta-analysis of randomized trials.Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease StudyGroup. Ann Intern Med 1997; 127: 337-34584. Fliser D, Schroter M, Neubeck M, Ritz E. Coadministration of thiazides increases theefficacy of loop diuretics even in patients with advanced renal failure. Kidney Int1994; 46: 482-48885. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y.A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renalfailure and hypertension. Nephrol Dial Transplant 2005; 20: 349-35386. Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemidealone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995; 26:394-40087. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of theangiotensin II antagonist losartan in hypertensive patients with renal disease. JHypertens Suppl 1994; 12: S37-S4288. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combinationtherapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renaldisease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006;48: 8-2089. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combinationtreatment of angiotensin-II receptor blocker and angiotensin-converting-enzymeinhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.Lancet 2003; 361: 117-12490. Kunz R, Wolbers M, Glass T, Mann JF. The COOPERATE trial: a letter of concern.Lancet 2008; 371: 1575-157691. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan,ramipril, or both, in people at high vascular risk (the ONTARGET study): amulticentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-55392. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high riskfor vascular events. N Engl J Med 2008; 358: 1547-155993. Epstein M, Williams GH, Weinberger M et al. Selective aldosterone blockade witheplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am SocNephrol 2006; 1: 940-95194. Ogawa S, Takeuchi K, Mori T, Nako K, Ito S. Spironolactone further reduces urinaryalbumin excretion and plasma B-type natriuretic peptide levels in hypertensive type IIdiabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp PharmacolPhysiol 2006; 33: 477-47936

More magazines by this user
Similar magazines